Credit: Thinkstock. KPI-012 is a topically dosed ophthalmic therapy designed using the Company's human mesenchymal stem cell secretome platform. The Food and Drug Administration (FDA) has granted Fast ...
Please provide your email address to receive an email when new articles are posted on . All eyes that received a single-layer graft and a 24-hour pressure patch showed complete healing. A three-layer ...
ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization ...
Japan's R-Tech Ueno has bought development and commercialization rights for DE-105 to treat persistent corneal epithelial defects from Santen Pharmaceutical in a deal that follows disappointing Phase ...
Eric Donnenfeld’s corneal health case presentations and panel discussion at OSN New York are always popular with meeting ...
Credit: Glaukos. Epioxa does not require the removal of the corneal epithelium, a step usually required by traditional corneal cross-linking procedures, thereby minimizing pain and recovery time.
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no ...
This study identifies mechanisms of epithelial growth post-SMILE surgery and suggests preventive and treatment measures, including subflap debris removal, to address corneal epithelial ingrowth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback